Literature DB >> 19952870

Thiopurine pathway.

Gianluigi Zaza1, Meyling Cheok, Natalia Krynetskaia, Caroline Thorn, Gabriele Stocco, Joan M Hebert, Howard McLeod, Richard M Weinshilboum, Mary V Relling, William E Evans, Teri E Klein, Russ B Altman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19952870      PMCID： PMC3098750          DOI： 10.1097/FPC.0b013e328334338f

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  30 in total

1.  Mechanisms of NT5C2-Mediated Thiopurine Resistance in Acute Lymphoblastic Leukemia.

Authors:  Takaya Moriyama; Shuguang Liu; Jing Li; Julia Meyer; Xujie Zhao; Wentao Yang; Youming Shao; Richard Heath; Aleš Hnízda; William L Carroll; Jun J Yang
Journal:  Mol Cancer Ther       Date:  2019-07-29       Impact factor: 6.261

Review 2.  Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.

Authors:  Tiphaine Adam de Beaumais; Evelyne Jacqz-Aigrain
Journal:  Eur J Clin Pharmacol       Date:  2012-03-16       Impact factor: 2.953

3.  NUDT15 genotyping in Caucasian patients can help to optimise thiopurine treatment in patients with inflammatory bowel disease.

Authors:  Marieke J H Coenen
Journal:  Transl Gastroenterol Hepatol       Date:  2019-12-12

4.  Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.

Authors:  Mary V Relling; Matthias Schwab; Michelle Whirl-Carrillo; Guilherme Suarez-Kurtz; Ching-Hon Pui; Charles M Stein; Ann M Moyer; William E Evans; Teri E Klein; Federico Guillermo Antillon-Klussmann; Kelly E Caudle; Motohiro Kato; Allen E J Yeoh; Kjeld Schmiegelow; Jun J Yang
Journal:  Clin Pharmacol Ther       Date:  2019-01-20       Impact factor: 6.875

5.  PharmGKB: the Pharmacogenomics Knowledge Base.

Authors:  Caroline F Thorn; Teri E Klein; Russ B Altman
Journal:  Methods Mol Biol       Date:  2013

Review 6.  Germline oncopharmacogenetics, a promising field in cancer therapy.

Authors:  Chiara Pesenti; Milena Gusella; Silvia M Sirchia; Monica Miozzo
Journal:  Cell Oncol (Dordr)       Date:  2015-01-09       Impact factor: 6.730

7.  Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.

Authors:  Natalia Sutiman; Sylvia Chen; Khoon Lin Ling; Sai Wei Chuah; Wai Fook Leong; Vinayak Nadiger; Madeline Tjai; Chris San Choon Kong; Brian John Schwender; Webber Chan; Hang Hock Shim; Wee Chian Lim; Chiea Chuen Khor; Yin Bun Cheung; Balram Chowbay
Journal:  Pharmacogenomics       Date:  2017-12-06       Impact factor: 2.533

8.  Exome sequencing and array-based comparative genomic hybridisation analysis of preferential 6-methylmercaptopurine producers.

Authors:  E W Chua; S Cree; M L Barclay; K Doudney; K Lehnert; A Aitchison; M A Kennedy
Journal:  Pharmacogenomics J       Date:  2015-03-10       Impact factor: 3.550

9.  Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.

Authors:  Alice Matimba; Fang Li; Alina Livshits; Cher S Cartwright; Stephen Scully; Brooke L Fridley; Gregory Jenkins; Anthony Batzler; Liewei Wang; Richard Weinshilboum; Lynne Lennard
Journal:  Pharmacogenomics       Date:  2014-03       Impact factor: 2.533

Review 10.  Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine.

Authors:  Laura L Daniel; Alyson L Dickson; Cecilia P Chung
Journal:  Clin Rheumatol       Date:  2020-07-02       Impact factor: 2.980
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.